Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[north40000]

LGND summary from 02/11/2014:

>>> Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

Financial highlights for the fourth quarter of 2013 include (all comparisons are with the fourth quarter of 2012):

Total revenues increased 8% to $14.7 million, and royalty revenues increased 48% to $7.1 million
Non-GAAP net income per share from continuing operations was $0.35 per diluted share
Net income increased 76% to $1.9 million, or $0.09 per diluted share

A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table titled “Non-GAAP Financial Measures.”

“2013 was a spectacular year for Ligand, and we believe we are well positioned for continued significant growth in 2014 and beyond. Throughout 2013 the remarkable progress of several partnered programs drove major contributions to our financial results and established a strong foundation for further growth in revenues and earnings,” commented John Higgins, President and Chief Executive Officer of Ligand. “Impressive operating and financial momentum continues to define Ligand with projected growth of our lead products, the recent launch of DuaveeTM, as many as four new revenue-generating products that may be approved in 2014 and partners expected to invest more than $800 million in Ligand programs this year across a vast array of promising assets.” <<<

Long wait from my initial entry @ $6.30, now a 1100% gain/share.